Details

Autor(en) / Beteiligte

• Bardet, Chloé
• Barraud, Olivier
• Clavel, Marc
• Fortin, Tanguy
• Charrier, Jean-Philippe
• Rodrigue, Marc
• François, Bruno
• Yugueros-Marcos, Javier
• Lemoine, Jerome
• Ploy, Marie-Cécile

Titel

Early and specific targeted mass spectrometry-based identification of bacteria in endotracheal aspirates of patients suspected with ventilator-associated pneumonia

Ist Teil von

• European journal of clinical microbiology & infectious diseases, 2021-06, Vol.40 (6), p.1291-1301

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2021

Link zum Volltext

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• Rapid and reliable pathogen identification is compulsory to confirm ventilator-associated pneumonia (VAP) in order to initiate appropriate antibiotic treatment. In the present proof of concept, the effectiveness of rapid microorganism identification with a targeted bottom-up proteomics approach was investigated in endotracheal aspirate (ETA) samples of VAP patients. To do so, a prototype selected-reaction monitoring (SRM)-based assay was developed on a triple quadrupole mass spectrometer tracking proteotypic peptide surrogates of bacterial proteomes. Through the concurrent monitoring of 97 species-specific peptides, this preliminary assay was dimensioned to characterize the occurrence of six most frequent bacterial species responsible for over more than 65% of VAP. Assay performance was subsequently evaluated by analyzing early and regular 37 ETA samples collected from 15 patients. Twenty-five samples were above the significant threshold of 10 5  CFU/mL and five samples showed mixed infections (both pathogens ≥ 10 5  CFU/mL). The targeted proteomics assay showed 100% specificity for Acinetobacter baumannii , Escherichia coli , Haemophilus influenzae , Pseudomonas aeruginosa , Staphylococcus aureus , and Streptococcus pneumoniae . No false bacterial identification was reported and no interference was detected arising from the commensal flora. The overall species identification sensitivity was 19/25 (76%) and was higher at the patient level (84.6%). This successful proof of concept provides a rational to broaden the panel of bacteria for further clinical evaluation.